Sherene Loi, MD, PhD

home / authors / sherene-loi-md-phd

Articles

21 Ribociclib (RIB) + Nonsteroidal Aromatase Inhibitor (NSAI) as Adjuvant Treatment in Patients (pts) With HR+/HER2– Early Breast Cancer (EBC): Final Invasive Disease-Free Survival (iDFS) Analysis From the NATALEE Trial

21 Ribociclib (RIB) + Nonsteroidal Aromatase Inhibitor (NSAI) as Adjuvant Treatment in Patients (pts) With HR+/HER2– Early Breast Cancer (EBC): Final Invasive Disease-Free Survival (iDFS) Analysis From the NATALEE Trial

Gabriel N. Hortobagyi, MD, FACP;Daniil Stroyakovskiy;Denise A. Yardley, MD;Chiun-Sheng Huang;Peter A. Fasching;John Crown;Aditya Bardia, MD, MPH;Stephen Chia;Seock-Ah Im;Miguel Martin, MD, PhD;Sherene Loi, MD, PhD;Binghe Xu;Sara A. Hurvitz, MD;Carlos Barrios;Michael Untch, MD, PhD;Rebecca Moroose;Frances Visco;Federico Parnizari;Farhat Ghaznawi;Zheng Li;Sorcha Waters;Arunava Chakravartty;Dennis J. Slamon, MD, PhD
August 7th 2024
Novel Therapies in Development for HER2-Amplified Breast Cancer

Novel Therapies in Development for HER2-Amplified Breast Cancer

Sherene Loi, MD, PhD
June 27th 2017

In this interview we discuss some of the novel therapeutics in development for HER2-amplified breast cancer.

Site Logo

Immune Targeting in Breast Cancer: In Whom and With What?

Sherene Loi, MD, PhD
May 15th 2015

The future role of immunotherapy in breast cancer is currently being actively investigated, so we anticipate that we will soon have further clues about the role of immunotherapy in breast cancer patients.

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Patient With Supraglottic Squamous Cell Carcinoma Develops Painful Swelling on Both Great Toes
Published: August 26th 2011 | Updated: May 18th 2025
Patient With Supraglottic Squamous Cell Carcinoma Develops Painful Swelling on Both Great Toes